CKD anemia content reviewed November 6, 2026 against KDIGO 2026. Population-specific rules are in the Evidence section below and in the CKD anemia guide.
- Enter the ESA, Hb, Hb change over a documented 2–4-week interval, current dose, and weeks since the last change.
- Review the action; a dose example is not a standing order.
- For initiation, select dialysis status and review the individualized decision before considering any displayed starting-dose example.
When to use
Use in adults with CKD anemia who are starting or receiving an ESA, to review initiation and dose changes against KDIGO 2026.
- Correct iron deficiency and other reversible causes first (TSAT & ferritin calculator).
- Not for children; pediatric targets are individualized by a pediatric nephrologist.
Interpretation and limitations
- Do not use an ESA to maintain Hb ≥11.5 g/dL; prefer dose reduction to holding when Hb approaches that level.
- Avoid adjustments more often than every 4 weeks unless Hb changes rapidly (rise >1 g/dL in 2–4 weeks).
- Persistently low Hb despite escalation suggests hyporesponsiveness; check iron, inflammation, bleeding, adequacy, and PTH before increasing further.
- Doses and conversions are product-specific; follow the local label.
ESA / EPO Dose Adjustment Calculator — CKD Anemia
Enter the ESA agent, current Hgb, the 2–4 week Hgb change, and the current weekly dose. The calculator applies the KDIGO 2026 adult decision-support rules to recommend dose review and monitoring guidance, and shows the suggested dose in the selected interval. Unit protocols vary — physician judgment is required.
Source: KDIGO 2026 Anemia in CKD, recommendations 2.1–2.4 and 3.2.1–3.3.1; practice points 2.2–2.8 and 3.4.1.2–3.4.3.5. Reviewed November 6, 2026. Apply clinical judgment and the locally approved product label.
ESA Initiation Calculator — ESA-Naïve Patients
For adults not yet on an ESA. Select the agent, weight, Hb, and dialysis setting. Initiation is individualized; displayed doses are KDIGO Table 7 examples only if treatment is prescribed.
Source: KDIGO 2026 Anemia in CKD, recommendations 2.1–2.4 and 3.2.1–3.3.1; practice points 2.2–2.8 and 3.4.1.2–3.4.3.5. Reviewed November 6, 2026. Apply clinical judgment and the locally approved product label.
Next steps
- Recheck Hb 2–4 weeks after initiation or any dose change.
- During stable maintenance, check Hb at least every 3 months (usually monthly in HD).
- Calculate the ESA resistance index when response seems inadequate.
Evidence and clinical rules
| Decision | KDIGO 2026 guidance |
|---|---|
| Adult HD or PD: consider initiation | After reversible causes are addressed, consider ESA when Hb is ≤9–10 g/dL. Select the threshold within that range using symptoms, risks, and patient preferences. |
| Non-dialysis CKD, including transplant recipients | Individualize initiation using symptoms, potential benefit, transfusion avoidance, ESA risks, and preferences; Hb <10 alone is not an automatic start order. |
| Adult maintenance goal | Target Hb below 11.5 g/dL (115 g/L), individualized. A common working range is about 10 to <11.5 g/dL; this is not an anemia diagnostic range. |
| Dose changes | Use the lowest effective dose. Generally avoid adjustments more often than every 4 weeks. If Hb rises >1 g/dL in 2–4 weeks, reduce by 25–50%. Prefer reduction to holding while Hb does not exceed 11.5, as clinically appropriate. |
| Monitoring | Hb every 2–4 weeks after initiation or adjustment; at least every 3 months during maintenance, usually more often in HD. |
| Stroke, thrombosis, and cancer | Consider suspending ESA during hospitalization for acute stroke, vascular access thrombosis, or thromboembolism. Active or previous cancer calls for shared decision-making, especially when treatment aims at cure. Uncontrolled hypertension and product-specific contraindications require review. |
| Agent | Adult non-dialysis CKD examples | Adult HD/PD examples |
|---|---|---|
| Epoetin alfa / beta | About 50 U/kg once or twice weekly; adapt to regional product label. | 50–100 U/kg three times weekly; confirm product and route. |
| Darbepoetin | 0.45 µg/kg weekly, or 40–100 µg every 2–4 weeks, individualized. | 0.45 µg/kg weekly or 0.75 µg/kg every 2 weeks. |
| Methoxy polyethylene glycol–epoetin beta (CERA) | 0.6 µg/kg every 2 weeks; other monthly regimens are product-specific. | 0.6 µg/kg every 2 weeks; conversion and monthly maintenance require product-label review. |
Examples are from KDIGO 2026 Table 7 (S55), not interchangeable prescriptions. Do not infer injection frequency from a weekly total or switch products using an unvalidated ratio. Use the locally approved label, route, vial strengths, and facility protocol.
Source: KDIGO 2026 Anemia in CKD, recommendations 2.1–2.4 and 3.2.1–3.3.1; practice points 2.2–2.8 and 3.4.1.2–3.4.3.5. Reviewed November 6, 2026. Apply clinical judgment and the locally approved product label.
